Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis.

Literature DB >> 11709356

In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis.

L Vera-Cabrera¹, A Gómez-Flores, W G Escalante-Fuentes, O Welsh.

Abstract

The in vitro activity of a novel oxazolidinone, linezolid, was studied by comparing the activity of linezolid with those of amikacin, trimethoprim-sulfamethoxazole, and amoxicillin-clavulanic acid against 25 strains of Nocardia brasiliensis isolated from patients with mycetoma. All N. brasiliensis strains tested were sensitive to linezolid (MIC at which 90% of strains are inhibited [MIC(90)], 2 microg/ml; MIC(50), 1 microg/ml). This antimicrobial might constitute a good alternative for treatment of actinomycetoma.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2001 PMID： 11709356 PMCID： PMC90885 DOI： 10.1128/AAC.45.12.3629-3630.2001

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

13 in total

Review 1. Mycetoma. Current concepts in treatment.

Authors: O Welsh
Journal: Int J Dermatol Date: 1991-06 Impact factor: 2.736

Review 2. Linezolid.

Authors: D Clemett; A Markham
Journal: Drugs Date: 2000-04 Impact factor: 9.546

3. Susceptibility testing of Nocardia species for the clinical laboratory.

Authors: R J Wallace; L C Steele
Journal: Diagn Microbiol Infect Dis Date: 1988-03 Impact factor: 2.803

4. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.

Authors: G A Noskin; F Siddiqui; V Stosor; D Hacek; L R Peterson
Journal: Antimicrob Agents Chemother Date: 1999-08 Impact factor: 5.191

5. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.

Authors: M J Rybak; D M Cappelletty; T Moldovan; J R Aeschlimann; G W Kaatz
Journal: Antimicrob Agents Chemother Date: 1998-03 Impact factor: 5.191

6. Linezolid, critical characteristics

Authors:
Journal: Infection Date: 2000-01 Impact factor: 3.553

7. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.

Authors: D L Shinabarger; K R Marotti; R W Murray; A H Lin; E P Melchior; S M Swaney; D S Dunyak; W F Demyan; J M Buysse
Journal: Antimicrob Agents Chemother Date: 1997-10 Impact factor: 5.191

8. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors: G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal: Antimicrob Agents Chemother Date: 1996-04 Impact factor: 5.191

9. [Epidemiology of mycetoma in Mexico: study of 2105 cases].

Authors: R López Martínez; L J Méndez Tovar; P Lavalle; O Welsh; A Saúl; E Macotela Ruíz
Journal: Gac Med Mex Date: 1992 Jul-Aug Impact factor: 0.302

Review 10. Oxazolidinones: a review.

Authors: D I Diekema; R N Jones
Journal: Drugs Date: 2000-01 Impact factor: 11.431

9 in total

1. Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.

Authors: Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jeng Teng; Po-Ren Hsueh
Journal: Antimicrob Agents Chemother Date: 2007-01-12 Impact factor: 5.191

Review 9. Mycetoma medical therapy.

Authors: Oliverio Welsh; Hail Mater Al-Abdely; Mario Cesar Salinas-Carmona; Ahmed Hassan Fahal
Journal: PLoS Negl Trop Dis Date: 2014-10-16

9 in total

In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis.

Review 1. Mycetoma. Current concepts in treatment.

Review 2. Linezolid.

3. Susceptibility testing of Nocardia species for the clinical laboratory.

4. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.

5. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.

6. Linezolid, critical characteristics

7. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.

8. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

9. [Epidemiology of mycetoma in Mexico: study of 2105 cases].

Review 10. Oxazolidinones: a review.

1. Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.

2. Intractable cerebral Nocardia mexicana in a GvHD patient successfully treated with linezolid.

3. [Disseminated nocardiosis : Diagnostic challenge].

Review 4. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy.

Review 5. Resistance to macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone antibiotics.

6. In vitro activities of new antimicrobials against Nocardia brasiliensis.

7. In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis.

8. In vitro activities of new quinolones and oxazolidinones against Actinomadura madurae.

Review 9. Mycetoma medical therapy.